

CURRENT RESEARCH
IN
MUSCULAR DYSTROPHY, JAPAN
(BIOMEDICAL RESEARCHES)

Vol. 2

The Proceedings of the
Annual Meeting of Muscular
Dystrophy Research Group,
1980, Tokyo

CONTENTS

Latent Muscular Dystrophy in Genotypically Dystrophic-dwarf Mice	1
Autoradiographic Studies on the Regeneration of Transplanted Muscles	3
Muscle Transplantation in the Etiological Elucidation of Avian Muscular Dystrophy	5
The Ectopic Differentiation of Striated Muscles in Rat Pineal Body Cell Culture	7
Tissue Culture Studies of Dystrophic Muscles	9
Mitotic Activities of Mononucleate Cells Cultured <i>In vitro</i> Originated from Regenerating Muscles of Normal (+/+) and Dystrophic (dy/dy) Mice	11
A Factor Extracted from the Brain Affecting Development of Tetrodotoxin-sensitive Spike Potential in Cultured Chick Skeletal Muscle	13
Class Specificity of Sera and Muscle Trophic Factor for Muscle Cell Growth <i>In vitro</i>	15
A Freeze Fracture Study of the Plasma Membrane of Dystrophic Chick Muscles	17
Structural Diversity in Chicken Skeletal Muscles	19
Troponin in Cardiac and Skeletal Muscles in Chicken Embryos Studied by Immunofluorescence Microscopy	21
Immunoelectronmicroscopic Observations of the Localization of Troponin Along the Thin Filament of Dystrophic Chicken Breast Muscle	23
Developmental Studies of the Membrane Properties of Striated Muscle Fibers	25
Shortening Velocity of Skinned Muscle Fibers from Dystrophic Chicken Muscles	27
Study of the Electrophysiological, Morphological, and Metabolic Aspects of Dystrophic Chick Muscle Membrane in Culture	29
Properties of Muscle Fiber and Neuro-muscular Transmission in Anthracene-9-carboxylic Acid-induced Myotonia	31
Mechanism of the Increase in Protein Synthetic Activity in Chicken Dystrophic Muscle	33
The Proportion of Monomeric and Polymeric Actins in Embryonic and Dystrophic Chicken Skeletal Muscles	35
Neonatal Denervation of Rat Sciatic Nerve. I. The Effect of Denervation on Myosin Differentiation	37
Connectin, an Elastic Protein of Muscle	39
Membrane Composition and Ca-uptake Ability of Sarcoplasmic Reticulum from Dystrophic Chicken..	41
Studies of Myelin-associated Enzymes in the Central Nervous System of Murine Muscular Dystrophy	43
Mode of Proteolysis of Myofibrillar Structural Proteins by Cathepsin-B	45
Enzymatic Relations in Dystrophic Mice and Chickens	47

Studies on Neutral Proteases in Muscle 49
The Effect of Calcium Ions on Calcium-activated Neutral Proteinase 51
Effect of *N*-[*N*-(*L*-*trans*-3-Carboxyoxirane-2-carbonyl)-*L*-leucyl]-3-methyl-butylamine, a Protease
Inhibitor, on Protein Degradation in Intact Muscle Cells 53
The List of Members the Research Group on Muscular Dystrophy in Japan (Biomedical Sciences) 55

LATENT MUSCULAR DYSTROPHY IN GENOTYPICALLY DYSTROPHIC-DWARF MICE

Tsuyoshi Totsuka, Kimi Watanabe, and Sigehiro Kiyono

Department of Physiology, Institute for Developmental Research, Aichi Prefectural Colony, Aichi

We have proposed a working hypothesis for the development of murine muscular dystrophy, as summarized in Fig. 1. This is based on the following experimental results. In muscular dystrophic mice (*dy/dy*; strain C57BL/6J-*dy*), the forelegs seemed to function almost normally even at 3 months of age, whereas the hindlegs showed characteristic signs of the disease at an early age (about 2 weeks), suggesting that comparative studies on the fore- and hindleg muscles might yield clues clarifying the mechanism involved in the development of murine muscular dystrophy. However, the forelegs of dystrophic mice were also found to be affected by the disease at least by 1 month of age. Thus, the endurance of the forelegs was much less than that in normal mice¹⁾. Moreover, it was found that the foreleg muscles, as well as the hindleg muscles^{2,3)}, were abnormal in collagen content⁴⁾, in the level of protease activities⁵⁾, and in the histological images (unpublished results from our laboratory). Also, the growth of the fore- and hindleg muscles was arrested at about 1 month of age. From a biochemical study of the hindleg muscles, the drastic increase in the apparent volume per muscle cell which occurs on and after 10 days of age in normal development was not observable in dystrophic mice⁶⁾. Findings thus far showed that there was no remarkable difference to explain the variation in the degree of apparent severity of the fore- and hindleg involvement in any feature of the muscles but rather the difference was in the growth of the bones⁷⁾. The growth (lengthening) of the foreleg bones was much smaller and slower than that of the hindleg bones during the period from 10 to 20 days of age in muscular dystrophic mice as well as in normal mice. It is noteworthy that the onset of the disease observable in the hindlegs (about 14 days of age) occurred in this period.

According to our working hypothesis, the clinical signs of the disease must be alleviated in dystrophic mice in which growth, including bone-lengthening, was arrested. To investigate this, a few effective methods are available at present, such as hypophysectomy and genetic methods. Genes *bm* (brachymorphic), *bp*




Fig. 1




Fig. 2

Fig. 1. A working hypothesis for the development of murine muscular dystrophy.

Fig. 2. Latent muscular dystrophy in genotypically dystrophic-dwarf mice. The genotypically dystrophic-dwarf mice (Nos. 3 and 4) were not dystrophic till they were treated with GH and T₄. f, m: female, male, respectively.

(brachypod), brp (another brachypod), and dw (pituitary dwarf) may be suitable for the purpose. We have already succeeded in producing genotypically dystrophic-brachymorphic (dy/dy•bm/bm), dystrophic-brachypod (dy/dy•brp/brp), and dystrophic-dwarf (dy/dy•dw/dw) mice. In the present study, results for dystrophic-dwarf mice are reported. In order to obtain dystrophic-dwarf mice, crosses were performed between F1 hybrid carriers (dy/+•dw/+), which were produced by crossing C57BL/6J-dystrophic carriers (dy/+•+/+) with DW/J-dwarf⁸⁾ carriers (+/+•dw/+; purchased from the Jackson Laboratory). In the F2 hybrid mice, phenotypically normal, dystrophic, and dwarf mice were observed but not the dystrophic-dwarf type. All the mice tested in our wire-net-climbing (WNC) apparatus⁹⁾, except for the dystrophic ones which continually dragged their hindlegs after about 3 months of age, showed almost normal locomotive activities even at 4.5 months of age (Fig. 2). Some of the phenotypically dwarf mice, however, began to manifest an abnormal sign in their eyes with age, which is a characteristic of murine muscular dystrophy. From this and the theoretical expectation (*i.e.*, one-sixteenth of the F2 hybrid mice should be genotypically dystrophic-dwarf mice), it was suggested that the dystrophic-dwarf mice were latent in the phenotypically dwarf ones. In fact, this was demonstrated by the following experiments.

F2 hybrid dwarf mice were injected intraperitoneally with bovine growth hormone (GH) and thyroxine (T₄). As the phenotypically dwarf mice grew with the GH-T₄-treatment (100 µg GH and 10 µg T₄/day¹⁰⁾, every other day for about 15 days), some of them began to exhibit the characteristic clinical signs of muscular dystrophy (sometimes dragging their hindlegs and revealing depressed activity in the WNC apparatus). Thus, genotypically dystrophic-dwarf mice could be identified. These dystrophic-dwarf mice had less muscle in their hindlegs than the nondystrophic dwarf mice which had been raised with GH-T₄-treatment. Five dystrophic-dwarf mice have been observed thus far.

From the present findings, it was concluded that muscular dystrophy was latent in genotypically dystrophic-dwarf (dy/dy•dw/dw) mice in which growth had been arrested by the gene dw. This suggests that hypophysectomy may be an effective symptomatic treatment for murine muscular dystrophy.

- 1) Watanabe, K. and Totsuka, T.: *Med. Biol.*, **99**, 171–173, 1979.
- 2) Totsuka, T. and Watanabe, K.: *Med. Biol.*, **94**, 327–329, 1977.
- 3) Totsuka, T. and Watanabe, K.: *Med. Biol.*, **97**, 235–237, 1978.
- 4) Watanabe, K. and Totsuka, T.: *Med. Biol.*, **98**, 257–260, 1979.
- 5) Totsuka, T. and Watanabe, K.: *Med. Biol.*, **98**, 149–152, 1979.
- 6) Watanabe, K. and Totsuka, T.: *Med. Biol.*, **93**, 203–206, 1976.
- 7) Totsuka, T. and Watanabe, K.: *Med. Biol.*, **99**, 1–5, 1979.
- 8) Snell, G.D.: *Proc. Natl. Acad. Sci. U.S.A.*, **15**, 733–734, 1929.
- 9) Totsuka, T., Watanabe, K., and Sano, M.: *Current Research in Muscular Dystrophy, Japan*, pp. 74–75, 1977.
- 10) Totsuka, T. and Watanabe, K.: *Med. Biol.*, **99**, 335–337, 1979.

